666 studies found for:    trastuzumab
Show Display Options
RSS Create an RSS feed from your search for:
trastuzumab
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
3 Completed Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Conditions: Breast Cancer;   Breast Neoplasms
Interventions: Drug: XL147 (SAR245408);   Biological: trastuzumab;   Drug: paclitaxel
4 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
5 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
6 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
7 Active, not recruiting A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: HKI-272;   Drug: Herceptin
8 Completed Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Biological: trastuxumab;   Drug: Docetaxel
9 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
10 Recruiting A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).
Condition: Brest Cancer
Interventions: Drug: Trastuzumab subcutaneous inyection vial;   Device: Trastuzumab subcutaneous device administration
11 Recruiting Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Neratinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide
12 Completed A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Conditions: Locally Advance Breast Cancer (LABC);   Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll);   Drug: Lapatinib + Capecitabine (Phase II)
13 Withdrawn Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Condition: Breast Cancer
Interventions: Drug: AMG 479;   Drug: Trastuzumab
14 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
15 Recruiting Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Condition: Breast Neoplasms
Interventions: Drug: Trastuzumab;   Drug: pertuzumab;   Drug: lapatinib
16 Completed Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Condition: Solid Tumors
Intervention: Radiation: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
17 Active, not recruiting Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Trastuzumab;   Drug: Cisplatin
18 Active, not recruiting Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: PF03512676;   Other: Correlative Studies
19 Completed
Has Results
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048AM2)(COMPLETED)
Condition: Breast Neoplasm
Interventions: Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab;   Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel
20 Active, not recruiting A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Condition: Breast Cancer
Interventions: Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel;   Drug: trastuzumab emtansine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years